Valuation: Alvotech

Market Cap 1.42B 1.22B 1.14B 1.05B 1.97B 136B 2B 13.46B 5.27B 68.27B 5.35B 5.23B 226B P/E 2026 *
15x
P/E 2027 * 8.7x
Enterprise Value 2.51B 2.15B 2.01B 1.84B 3.47B 240B 3.52B 23.7B 9.28B 120B 9.42B 9.21B 397B EV / Sales 2026 *
3.82x
EV / Sales 2027 * 3.18x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+1.01%
Current month-57.46%
Current year-57.46%
5 years 3.94
Extreme 3.94
10.44
10 years 3.94
Extreme 3.94
11.62
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
21/9/20 OthersCompany 218,750 3.8889%
16/9/20 OtherCompany 0 0%
16/9/20 OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%-0.50% - - 1.42B
+0.66%+2.30%+3.39%+22.74% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+0.17%+0.57%+2.44%+31.14% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +1.90%+2.01%+84.50%+128.46% 30.51B
Weighted average by Cap. +1.79%+2.37%+104.80%+154.16%

Financials

2026 *2027 *
Net sales 656M 563M 525M 482M 906M 62.69B 921M 6.2B 2.43B 31.44B 2.46B 2.41B 104B 779M 668M 624M 572M 1.08B 74.46B 1.09B 7.36B 2.88B 37.34B 2.93B 2.86B 123B
Net income 91.8M 78.74M 73.53M 67.46M 127M 8.77B 129M 868M 340M 4.4B 345M 337M 14.55B 151M 130M 121M 111M 209M 14.47B 213M 1.43B 560M 7.26B 568M 556M 23.99B
Net Debt 1.08B 929M 868M 796M 1.5B 104B 1.52B 10.24B 4.01B 51.94B 4.07B 3.98B 172B 1.06B 906M 846M 776M 1.46B 101B 1.48B 9.98B 3.91B 50.62B 3.97B 3.88B 167B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
19/08/26 USD 3.990 +1.01% 546,895
18/08/26 USD 3.950 +1.80% 675,582
17/08/26 USD 3.880 -4.32% 591,717
14/08/26 USD 4.055 -0.86% 607,270
13/08/26 USD 4.090 +2.00% 559,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.990USD
Average target price
5.750USD
Spread / Average Target
+44.11%

Quarterly revenue - Rate of surprise